News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Mitchell Kamrava, MD

Articles by Mitchell Kamrava, MD

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

ByJun Gong, MD,Edwin M. Posadas, MD,Neil Bhowmick, PhD,Hyung L. Kim, MD,Timothy J. Daskivich, MD,Amit Gupta, MD,Howard M. Sandler, MD,Mitchell Kamrava, MD,Zachary S. Zumsteg, MD,Stephen J. Freedland, MD,Robert A. Figlin, MD

March 17th 2021

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Latest Updated Articles

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
Published: March 17th 2021 | Updated:

Trending on CancerNetwork

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

© 2025 MJH Life Sciences^®

All rights reserved.